Obesity Market to Accelerate Substantially During the Forecast Period (2023-2032) - DelveInsight | Eli Lilly, Novartis, Novo Nordisk, Otsuka, Pfizer, Regeneron, RosVivo, Saniona, SciSparc, AstraZeneca, Shionogi, Aardvark, Enterin, Agentix, Altimmune

The obesity market is undergoing a significant transformation with a shift towards personalized treatments and holistic approaches to weight management. Emerging pharmaceuticals, coupled with advancements in bariatric surgery techniques and increased awareness of lifestyle interventions, are reshaping the landscape. Additionally, there's a growing emphasis on addressing obesity-related comorbidities, fostering a comprehensive approach to improve patient outcomes and overall health.

DelveInsight's "Obesity Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Obesity Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Obesity therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Obesity treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Obesity: An Overview
Obesity is recognized as a chronic or noncommunicable disease, which is a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity, or body fatness which can manifest metabolically and not just with respect to the size of the body.

As per the World Health Organization (WHO), obesity is classified on the basis of body mass index (BMI). BMI is further evaluated in terms of fat distribution via the waist-to-hip ratio and total cardiovascular risk factors. In children, a healthy weight varies according to age and sex.

Due to the psychological and social stigma associated with being overweight and obese, those affected are also vulnerable to discrimination in their personal and work lives, low self-esteem, and depression. Childhood obesity results in the same comorbidities as obesity, with premature onset or with a greater likelihood in adulthood.

Obesity results from an interaction between an individual's genetic predisposition to weight gain and environmental influences. The severe forms and the majority of the early-onset monogenic forms of obesity have aroused from gene mutations in the leptin-melanocortin axis, particularly LEPR encoding for the leptin receptor, POMC (pro-opiomelanocortin), MC4R (melanocortin-4 receptor), NTRK2 (tropomyosin receptor kinase B receptor), and SIM1 (single-minded 1 transcription factor).

Obesity Market Key Facts
• In 2021, the total Obesity market size was USD 1,052 Million, which is expected to rise during the study period (2019-2032).
• The total Obesity market size in the United States accounted for USD 847 million in 2021 which is expected to rise during the study period (2019-2032).
• In EU5, the total Obesity market size was USD 185 million in 2021, which is expected to rise during the study period (2019-2032).
• In Japan, the total market size of obesity was USD 21 million in 2021, which is expected to rise during the study period (2019-2032).
• In the year 2021, the total obesity prevalent cases in adults (>19 years) was 182.22 Million (M), and in children (5-19 years) was 7.85 million in the 7MM which is expected to grow during the study period, i.e., 2019-2032.

Get a Detailed Overview of the Evolving Obesity Market Trends @
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Obesity Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Obesity therapies in the market. It also provides a detailed assessment of the Obesity market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Obesity drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Obesity Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Obesity Epidemiology
The epidemiology section covers detailed insights into the historical, and current Obesity patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Obesity Epidemiology Segmented as -
• Total prevalent cases of obesity
• Total obesity patients seeking help
• Total treated cases of obesity

Get Key Insights Into the Evolving Obesity Epidemiology Trends @
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Obesity Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obesity market or expected to be launched during the study period. The analysis covers the market share by Obesity drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Obesity Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Obesity Market @
https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Obesity Therapeutics Assessment
Early diagnosis and intervention is the most successful strategy for obesity treatment. Diagnosis of obesity involves proper evaluation of the weight status, which considers many factors and uses various tools and diagnostic tests, including body mass index (BMI), waist circumference measurement, physical exams, and lab tests to check for comorbidities.

There are more effective medications, procedures, and evidence-based treatments available for obesity today than 20 years ago, but healthcare professionals are still struggling to get treatment to more people. Obesity treatment in general is very challenging, in part because it's often not covered by payers. Up until 2003, Medicare had an explicit policy that said you could not consider obesity as a disease or a health condition. It was considered a cosmetic issue; it was explicitly excluded from any kind of Medicare treatment.

Losing weight through healthy eating, increasing physical activity, and making other lifestyle changes are all common therapies for obesity. Some people may benefit from weight-management programs in order to lose weight or avoid regaining it. Other therapies, such as weight-loss drugs, gadgets, or bariatric surgery, may be considered in such circumstances. The FDA has approved several prescription medications for weight loss management in the overweight and obese patient population.

The US FDA has approved XENICAL (orlistat), QSYMIA (phentermine-topiramate), CONTRAVE (naltrexone-bupropion), SAXENDA (liraglutide), WEGOVY (semaglutide), and IMCIVREE (setmelanotide)-for long-term use in overweight and obesity treatment. These therapies work by blocking the absorption of macronutrients; decreasing energy intake, and increasing energy expenditure.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Obesity. Currently, Novo Nordisk is leading the therapeutics market with its Obesity drug candidates in the most advanced stage of clinical development.

Leading Companies in the Obesity Therapeutics Market Include
Some of the key companies in the Obesity Therapeutics Market include 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Betagenon AB, BioRestorative, BioRestorative Therapies, Boehringer Ingelheim, Braasch Biotech, Bristol-Myers Squibb, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Carmot Therapeutics Inc, Cellivery Therapeutics Inc, CinFina, CinFina Pharma, Clayton Biotech, Click Therapeutics, CohBar, Corbus Pharma, CSPC Baike (Shandong) Biopharmaceutical, D&D Pharmatech, D&D Pharmatech Co Ltd, Daewoong Pharmaceutical, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc, EraCal Therapeutics AG, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Paige Biopharmaceutical (Suzhou) Co Ltd, Pfizer, Preveceutical Medical Inc, Pylum Biosciences, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, RosVivo Therapeutics, Saniona, SciSparc Ltd, Sciwind Biosciences, SCOHIA PHARMA, Shionogi, SHIONOGI & Co Ltd, Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others.

Emerging and Marketed Obesity Therapies Covered in the Report Include
Some of the emerging therapies in the Obesity therapeutics market include Semaglutide oral (Novo Nordisk), Tirzepatide (Eli Lilly and Company), RZL-012 (Raziel Therapeutics), Tesomet (Saniona), CT-868 (Carmot Therapeutics), EMP16 (Empros Pharma), DD01 (D&D Pharmatech), ERX-1000 (ERX Pharmaceuticals), ZP 8396 (Zealand Pharma), and many more.

Learn More About the Emerging Therapies and key Companies in the Obesity Therapeutics Market @
https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Obesity Competitive Intelligence Analysis
4. Obesity Market Overview at a Glance
5. Obesity Background and Overview
6. Obesity Patient Journey
7. Obesity Epidemiology and Patient Population
8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices
9. Obesity Unmet Needs
10. Key Endpoints of Obesity Treatment
11. Obesity Marketed Products
12. Obesity Emerging Therapies
13. Obesity Seven Major Market Analysis
14. Attribute Analysis
15. Obesity Market Outlook (7 major markets)
16. Obesity Access and Reimbursement Overview
17. KOL Views on the Obesity Market.
18. Obesity Market Drivers
19. Obesity Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.